Bio-Techne Corp

TECH Healthcare Biotechnology

Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025. In the quarter to June 2026, revenue grew 1.33%, EPS grew 418.2%, free cash flow fell 6.83% and total debt fell 42.2%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for three consecutive years.

72.54 0.02 +0.03%
Market cap
$11.4B
P/E
62.0×
Fwd P/E
37.6×
Dividend yield
0.44%
F-score
9/9
Altman Z
15.50
Beneish M
−2.52
Dividend safety
78/100

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Older periods Sep '25 Dec '25 Mar '26 Jun '26
Total current assets
609.51 637.43 688.05 744.40
Total non-current assets
1,916.64 1,885.27 1,862.55 1,842.33
Total Assets
2,526.15 2,522.70 2,550.60 2,586.73
Total current liabilities
144.55 140.43 153.28 163.70
Total non-current liabilities
415.79 371.28 312.02 314.81
Total liabilities
560.33 511.71 465.30 478.51
Common Equity (Total)
1,965.81 2,010.99 2,085.30 2,108.22
Shareholders Equity (Total)
1,965.81 2,010.99 2,085.30 2,108.22
Total Debt
300.00 260.00 200.00 200.00

Show all line items

In millions of $ except per-share values · columns are period end dates